S. Korea Set To Allow Resumption Of Embryonic Stem Cell Research
This article was originally published in PharmAsia News
Executive Summary
South Korean Health Ministry and biotech industry officials reportedly have agreed to resume allowing stem cell research using cloned embryonic cells. They agreed the National Bioethics Committee would allow such research as early as April. The panel had delayed that decision earlier because a hospital that wanted to do similar research had not resolved controversial ethics issues. South Korea banned such research three years ago when it was revealed groundbreaking studies in the area had been fabricated. (Click here for more
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.